Study to Evaluate the Effect of GWP42003 on Liver Fat Levels in Participants With Fatty Liver Disease

NCT01284634 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Fatty Liver

Interventions

DRUG: GWP42003 200 mg/day Dose
DRUG: GWP42003 400 mg/day Dose
DRUG: GWP42003 800 mg/day Dose
DRUG: Placebo

Sponsor

GW Research Ltd